Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Soleno Therapeutics, Inc. from 2014 to 2023.

Sarepta's Strategic Growth

Sarepta Therapeutics has seen a dramatic increase in SG&A expenses, growing nearly tenfold from 2014 to 2023. This reflects the company's aggressive expansion and investment in its operations, with expenses peaking at approximately $482 million in 2023. Such growth indicates a robust strategy to capture market share and enhance its product offerings.

Soleno's Steady Path

In contrast, Soleno Therapeutics has maintained a more conservative approach, with SG&A expenses increasing modestly by about 360% over the same period. This steady growth suggests a focus on sustainable development and careful resource allocation.

Both companies illustrate different strategies in managing operational costs, offering valuable insights into the biotech industry's diverse approaches to growth and sustainability.